Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
- EligibilityCriteria: Inclusion Criteria:  * Subjects will have or had ovarian cancer and are on or have completed PARPi maintenance therapy  Or have been diagnosed with ovarian cancer as well as clonal hematopoiesis of indeterminate potential Have a life expectancy of greater than 6 months  Exclusion Criteria:  * Individuals with a life expectancy of less than 6 months - HealthyVolunteers: No - Gender: Female - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Subjects will have or had ovarian cancer and are on or have completed PARPi maintenance therapy or have been diagnosed with ovarian cancer as well as clonal hematopoiesis of indeterminate potential - SamplingMethod: Non-Probability Sample